Orchid Pharma Limited (BOM:524372)
773.10
-12.05 (-1.53%)
At close: Aug 22, 2025
Orchid Pharma Revenue
Orchid Pharma had revenue of 1.73B INR in the quarter ending June 30, 2025, a decrease of -29.25%. This brings the company's revenue in the last twelve months to 8.50B, down -3.45% year-over-year. In the fiscal year ending March 31, 2025, Orchid Pharma had annual revenue of 9.22B with 12.52% growth.
Revenue (ttm)
8.50B
Revenue Growth
-3.45%
P/S Ratio
4.61
Revenue / Employee
9.76M
Employees
871
Market Cap
39.17B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 9.22B | 1.03B | 12.52% |
Mar 31, 2024 | 8.19B | 1.53B | 23.05% |
Mar 31, 2023 | 6.66B | 1.06B | 19.00% |
Mar 31, 2022 | 5.60B | 1.09B | 24.33% |
Mar 31, 2021 | 4.50B | -337.41M | -6.97% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,503.84B |
Hindustan Unilever | 639.28B |
Infosys | 1,672.76B |
Orchid Pharma News
- 5 weeks ago - Top stocks to buy today: Stock recommendations for July 16, 2025 - check list - The Times of India
- 3 months ago - Orchid Pharma shares drop nearly 5% as Q4 net profit falls 32.4% YoY to Rs 22.3 crore - Business Upturn
- 6 months ago - Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility - Business Upturn
- 6 months ago - Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal - Business Upturn
- 6 months ago - Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3 - Business Upturn
- 10 months ago - Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results - Business Upturn
- 10 months ago - Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY - Business Upturn